Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01006005
First received: October 30, 2009
Last updated: November 20, 2012
Last verified: November 2012
  Purpose

The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room occupancy hotels and free meal food lines as part of the UCSF Reach Study. Adherence will be measured through monthly unannounced pill counts and electronic medication monitors.


Condition
HIV Infections
Adherence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Enrollment: 51
Study Start Date: July 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HIV infected, marginally housed

Criteria

Inclusion Criteria:

  • 18+ years old;
  • HIV+;
  • Initiating Atripla within 6-months of recruitment;
  • Lives in the Tenderloin, South of Market, or Mission District San Francisco;
  • Capable of providing informed consent; and
  • Willing to complete all study procedures.

Exclusion Criteria:

  • Intoxication, cognitive dysfunction or psychosis will preclude potential subjects from informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01006005     History of Changes
Other Study ID Numbers: IN-US-177-0106
Study First Received: October 30, 2009
Last Updated: November 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
HIV
Treatment experienced

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on November 20, 2014